|
|
Post by lakers on Oct 2, 2017 19:19:37 GMT -5
|
|
|
|
Post by peppy on Oct 2, 2017 19:48:02 GMT -5
Castagna said he anticipates a new agreement with a major pharmacy benefit manager by January 2018, as well as improved access with other payers, although these changes are typically not announced. Castagna has argued for some time that Afrezza is a “completely differentiated” product from competing mealtime insulins and deserves better consideration. “Payers don’t turn overnight on anything,” he said. “But if you take the label change, and the fact that we can now use a lot of the data we have, there is clearly a difference between us and other drugs.” |
|
|
|
Post by itellthefuture777 on Oct 3, 2017 10:50:51 GMT -5
Castagna said he anticipates a new agreement with a major pharmacy benefit manager by January 2018, as well as improved access with other payers, although these changes are typically not announced. Castagna has argued for some time that Afrezza is a “completely differentiated” product from competing mealtime insulins and deserves better consideration. “Payers don’t turn overnight on anything,” he said. “But if you take the label change, and the fact that we can now use a lot of the data we have, there is clearly a difference between us and other drugs.” NOVO Nordisk wants great tier placement...is my guess..and..Afrezza is faster in and out...so they can't get it without Afrezza also getting it..is my guess..like having a 90000lbs gorilla also asking for the same thing..hmm |
|
